Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Clinical features, antimicrobial susceptibilities, and outcomes of Elizabethkingia meningoseptica (Chryseobacterium meningosepticum) bacteremia at a medical center in Taiwan, 1999–2006
Ist Teil von
European journal of clinical microbiology & infectious diseases, 2011-10, Vol.30 (10), p.1271-1278
Ort / Verlag
Berlin/Heidelberg: Springer-Verlag
Erscheinungsjahr
2011
Quelle
MEDLINE
Beschreibungen/Notizen
A total of 118 patients with
Elizabethkingia meningoseptica
bacteremia at a medical center in Taiwan from 1999 to 2006 were studied. Minimum inhibitory concentrations (MICs) of 99 preserved isolates were determined. The incidence (per 100,000 admissions) of
E. meningoseptica
bacteremia increased from 7.5 in 1996 to 35.6 in 2006 (
p
= 0.006). Among them, 84% presented with fever, 86% had nosocomial infections, and 60% had acquired the infection in intensive care units (ICUs). The most common underlying diseases were malignancy (36%) and diabetes mellitus (25%). Seventy-eight percent of patients had primary bacteremia, followed by pneumonia (9%), soft tissue infection, and catheter-related bacteremia (6%). Forty-five patients (38%) had polymicrobial bacteremia. Overall, the 14-day mortality was 23.4%. Multivariate analysis revealed
E. meningoseptica
bacteremia acquired in an ICU (
p
= 0.048, odds ratio [OR] 4.23) and presence of effective antibiotic treatment after the availability of culture results (
p
= 0.049, OR 0.31) were independent predictors of 14-day mortality. The 14-day mortality was higher among patients receiving carbapenems (
p
= 0.046) than fluoroquinolones or other antimicrobial agents. More than 80% of the isolates tested were susceptible to trimethoprim-sulfamethoxzole, moxifloxacin, and levofloxacin. The MIC
50
and MIC
90
of the isolates to tigecycline and doxycycline were both 4 μg/mL and 8 μg/ml, respectively.